Left Atrial Appendage Closure Versus Direct Oral Anticoagulants in High-Risk Patients With Atrial Fibrillation (PRAGUE-17)
Source: View publication →
In patients with nonvalvular atrial fibrillation at high risk for both stroke and bleeding, percutaneous left atrial appendage closure (LAAC) was noninferior to treatment with direct oral anticoagulants (DOACs) regarding the composite primary endpoint of major cardiovascular and neurological events, with a secondary benefit of reduced nonprocedural clinically relevant bleeding.
Key Findings
Study Design
Study Limitations
Clinical Significance
The results suggest that percutaneous LAAC represents a viable, non-pharmacological alternative for stroke prevention in high-risk patients with atrial fibrillation who have a history of significant bleeding or intolerance to long-term oral anticoagulation, particularly as the long-term benefit of reduced nonprocedural bleeding becomes increasingly apparent.
Historical Context
Previous landmark trials for LAA closure (e.g., PROTECT-AF and PREVAIL) compared device intervention against vitamin K antagonists (warfarin). As direct oral anticoagulants (DOACs) became the standard of care due to a better safety and efficacy profile compared to warfarin, the PRAGUE-17 trial was essential to determine if LAA closure maintained its comparative effectiveness against the current gold-standard pharmacotherapy.
Guided Discussion
High-yield insights from every perspective
In the context of atrial fibrillation (AF), why is the left atrial appendage (LAA) the primary focus for stroke prevention, and what is the physiological trade-off between using a Direct Oral Anticoagulant (DOAC) and a mechanical closure device?
Key Response
In nonvalvular AF, over 90% of thrombi originate in the LAA due to stasis and endocardial remodeling. While DOACs provide systemic anticoagulation to prevent thrombus formation, they increase the risk of hemorrhage elsewhere (e.g., GI tract). Percutaneous LAAC offers a localized, mechanical solution to exclude the LAA from circulation, theoretically providing stroke protection without the lifelong systemic bleeding risk associated with anticoagulants.
PRAGUE-17 focused on a 'high-risk' population. What specific clinical criteria defined this cohort, and how should these findings influence your management of a patient with a CHA2DS2-VASc score of 4 who has experienced recurrent epistaxis on apixaban?
Key Response
The study included patients with a CHA2DS2-VASc ≥ 3 and a high bleeding risk (defined by HAS-BLED, history of major bleeding, or requirement for triple therapy). For a patient with a high stroke risk and clinically relevant bleeding on DOACs, PRAGUE-17 provides evidence that LAAC is noninferior to DOACs for net clinical benefit, making it a viable alternative to switching DOAC agents or doses which may not address the underlying bleeding tendency.
PRAGUE-17 utilized multiple LAAC devices (Watchman, Watchman FLX, Amulet) and a standardized post-procedural antithrombotic protocol. How does the occurrence of Device-Related Thrombus (DRT) in the LAAC arm impact the interpretation of the noninferiority results compared to the steady-state efficacy of DOACs?
Key Response
DRT remains a concern for LAAC, as it can be a source of systemic embolism despite mechanical exclusion. In PRAGUE-17, the noninferiority margin was met despite the procedural risks and DRT potential. Fellows must weigh the 'front-loaded' risk of LAAC (procedure-related events and DRT during endothelization) against the cumulative, linear risk of bleeding associated with DOACs over time.
Most prior LAAC trials (like PROTECT-AF) compared the device to warfarin. Given that PRAGUE-17 compared LAAC directly to DOACs—the current standard of care—does this trial provide enough evidence to move LAAC from a 'second-line' therapy to a 'co-first-line' option for patients who are eligible for, but at high risk on, anticoagulation?
Key Response
This question addresses the paradigm shift from using LAAC only as a 'salvage' therapy for those with contraindications to anticoagulation to using it as a primary strategy. While noninferiority to DOACs is a major milestone, attendings must consider that DOACs are easier to initiate and do not carry the acute procedural risks (pericardial effusion, etc.) seen in 4.5% of the PRAGUE-17 LAAC group.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
The primary endpoint of PRAGUE-17 was a composite of stroke, TIA, systemic embolism, cardiovascular death, and major/non-major clinically relevant bleeding. Critically analyze the risk of 'masking' ischemic outcomes within this net clinical benefit endpoint, especially when the noninferiority margin is relatively wide (HR 1.47).
Key Response
Using a composite endpoint that includes bleeding can favor the LAAC arm because LAAC significantly reduces nonprocedural bleeding. If a trial is powered for the composite, it might lack the power to detect a small but clinically significant increase in ischemic strokes in the LAAC arm that is 'offset' by the reduction in bleeding events, potentially leading to a 'noninferior' conclusion for a treatment that is less effective at its primary physiological goal (stroke prevention).
As a reviewer, how would you evaluate the impact of the open-label design and the high proportion of apixaban use (95% of the DOAC group) on the generalizability of the PRAGUE-17 findings to the broader class of DOACs and different clinical practice settings?
Key Response
Open-label trials are susceptible to bias in reporting subjective events like TIA or 'clinically relevant' bleeding. Furthermore, because apixaban is often considered the 'safest' DOAC regarding GI bleeding, the noninferiority of LAAC in this study is particularly robust; however, it remains a single-region study (Czech Republic), which may limit generalizability to global healthcare systems with different procedural expertise and follow-up standards.
Current ESC and AHA/ACC/HRS guidelines typically assign LAAC a Class IIb recommendation for patients with contraindications to long-term anticoagulation. Based on the PRAGUE-17 data showing noninferiority to DOACs, should the recommendation be upgraded to Class IIa for patients who are anticoagulation-eligible but at high bleeding risk?
Key Response
Guidelines currently emphasize LAAC as a 'fallback' (Class IIb, Level B-R). PRAGUE-17 provides the highest level of evidence to date comparing LAAC to the modern gold standard (DOACs). Committee members must decide if the reduction in nonprocedural bleeding is sufficient to warrant a Class IIa (should be considered) recommendation, moving it closer to being a standard-of-care alternative rather than just a secondary option.
Clinical Landscape
Noteworthy Related Trials
PROTECT AF Trial
Tested
Watchman LAA closure device
Population
Patients with non-valvular atrial fibrillation eligible for warfarin
Comparator
Warfarin
Endpoint
Composite of stroke, systemic embolism, and cardiovascular death
PREVAIL Trial
Tested
Watchman LAA closure device
Population
Patients with non-valvular atrial fibrillation at increased risk of stroke
Comparator
Warfarin
Endpoint
Composite of stroke, systemic embolism, and cardiovascular death
CLOSURE-AF
Tested
LAA closure with Amulet device
Population
Patients with atrial fibrillation and high bleeding risk
Comparator
Standard of care (DOAC or LAA closure)
Endpoint
Composite of cardiovascular death, stroke, and systemic embolism
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis